Abstract
Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but higher susceptibilities to isavuconazole.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antifungal Agents / pharmacology*
-
Aspergillus / drug effects*
-
Aspergillus / isolation & purification
-
Azoles / pharmacology
-
Communicable Diseases, Emerging / epidemiology
-
Communicable Diseases, Emerging / microbiology*
-
Cryptococcus gattii / drug effects*
-
Cryptococcus gattii / isolation & purification
-
Humans
-
Microbial Sensitivity Tests
-
Mycoses / epidemiology
-
Mycoses / microbiology*
-
Neosartorya / drug effects*
-
Neosartorya / isolation & purification
-
Nitriles / pharmacology*
-
North America
-
Pyridines / pharmacology*
-
Triazoles / pharmacology*
Substances
-
Antifungal Agents
-
Azoles
-
Nitriles
-
Pyridines
-
Triazoles
-
isavuconazole